Delcath Systems, Inc. (NASDAQ: DCTH), a leading developer of regional therapy for cancer, today announced that Dr. Charles Nutting of Swedish Medical Center in Englewood, Colorado will deliver a presentation at the 38th Annual Meeting of the Western Angiographic and Interventional Society (“WAIS”). Dr. Nutting will discuss his involvement with Delcath’s Phase III trial of its Percutaneous Hepatic Perfusion (PHP) System for the treatment of inoperable metastatic melanoma at the conference, held in Maui, Hawaii from September 20-25, 2008.
Dr. Nutting, a Principal Investigator on the Phase III trial, will present Delcath’s PHP technology and its role in the treatment of liver metastases. Dr. Nutting has been at the forefront of regional therapy for the treatment of cancer, and is a leader in the field of interventional oncologic techniques. He has recently joined the Delcath trial, as the Principal Investigator at Swedish Medical Center, one of the nine enrolling centers for the randomized Phase III trial.
“Dr. Nutting’s presentation marks an expansion in awareness for the Delcath PHP System,” stated Richard L. Taney, President and CEO of Delcath. “This is the first major presentation regarding the Phase III trial by an Investigator outside of the National Cancer Institute. As the oncology community becomes more familiar with the potential benefits of Delcath’s PHP technology, this presentation will further the awareness of the Interventional Radiology Community which will be a key driver in the adoption of this unique treatment for inoperable cancers.”
WAIS is a regional society of leading physicians from the western states and Canada dedicated to vascular and interventional radiology, and image-guided techniques for the diagnosis and treatment of cancer and other illnesses. Information on this organization and conference can be found at www.westernangio.org.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath’s novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient’s bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company’s intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company’s website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Company Contact: Delcath Systems, Inc. Richard Taney (212) 489-2100 Email Contact Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper/Cass Almendral (212) 838-1444 Email ContactEmail Contact Public Relations Contact: Rubenstein Associates, Inc. Robin Wagge (212) 843-8006 Email Contact
SOURCE: Delcath Systems, Inc.
Comments